3+ day, 3+ hour ago   (214+ words) Erica L. Mayer, MD, MPH, explained why oncologists should switch to camizestrant at ESR1 mutation emergence rather than reserve oral SERDs for progression. Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD Kamel Abou…...

3+ day, 6+ hour ago   (478+ words) ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer. A repeat chest CT on May 8, 2022, showed improvement in pulmonary findings, and a brain MRI performed on the same day showed stable intracranial disease without worsening....

3+ day, 7+ hour ago   (552+ words) Initial phase 2 SURF302 data show a 79% ORR with 60 mg once-daily oral dabogratinib in FGFR3-altered low-grade intermediate-risk NMIBC. Treatment with the oral FGFR3-selective inhibitor dabogratinib (TYRA-300) elicited responses and demonstrated a favorable safety profile in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive…...

4+ day, 11+ hour ago   (642+ words) The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma. Treatment with OST-HER2 (OST31-164) produced a statistically significant improvement in 3-year overall survival (OS) compared with a combined published…...

4+ day, 7+ hour ago   (369+ words) The FDA has granted accelerated approval to sevabertinib for metastatic non-squamous NSCLC with HER2 TKD activating mutations based on results from the SOHO-01 trial. The FDA has granted accelerated approval to sevabertinib (Hyrnuo) as a treatment for those with locally advanced…...

1+ week, 4+ day ago   (404+ words) The European Commission has approved T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer based on DESTINY-Breast09. The approval follows a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency and…...

1+ week, 4+ day ago   (244+ words) The safety profile of zanidatamab in combination with chemotherapy was generally consistent with the known safety profiles of the individual agents and with previously reported HERIZON-GEA-01 data. No new safety signals were observed with the extended follow-up, according to the…...

1+ week, 5+ day ago   (207+ words) Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, closes with the competitive landscape around capivasertib plus fulvestrant in hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Kamel Abou Hussein, MD; Yelda Nouri, MD Aditya Bardia, MD,…...

1+ week, 6+ day ago   (210+ words) Learn how biomarker testing guides second-line choices after CDK4/6 therapy in HR+ HER2- metastatic breast cancer, including PI3K/AKT/mTOR options. Sara A. Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD Kurt C. Demel, MD, MBA; Sara A. Hurvitz, MD, FACP Kamel Abou Hussein, MD; Yelda…...

1+ week, 6+ day ago   (207+ words) Learn how liquid and tissue biopsies uncover ESR1 and PI3K mutations to personalize metastatic breast cancer second-line therapy choices. Sara A. Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD Kurt C. Demel, MD, MBA; Sara A. Hurvitz, MD, FACP Kamel Abou Hussein, MD; Yelda Nouri,…...